POST APPROVAL VARIATION in USA

Post-Approval Variation (PAV) in the USA refers to changes made to an already approved drug application (e.g., NDA, ANDA, or BLA) after it has received marketing authorization from the U.S. Food and Drug Administration (FDA). These changes could involve modifications to the drug substance, drug product, manufacturing processes, packaging, labeling, or administrative information.

The process for managing post-approval changes in the USA is governed by the FDA under the Code of Federal Regulations (CFR) and specific guidelines like FDA’s Guidance for Industry: Changes to an Approved NDA or ANDA.

Types of Post-Approval Variations:

The FDA classifies post-approval changes into three categories based on the potential impact on product quality, safety, and efficacy:

1. Major Changes (Prior Approval Supplement – PAS):
   These changes require FDA approval before implementation. Examples include:

   • Changes in the manufacturing site for the drug substance or drug product.
   • Changes in the formulation of the drug.
   • Changes affecting the control strategy for drug substances/products.
   • Changes that may significantly affect the drug’s quality, safety, or efficacy.

2. Moderate Changes (Changes Being Effected – CBE):
   These changes can be implemented after FDA is notified through a supplement, although some require a 30-day review. Examples include:

   • Relaxation of a specification within an approved range.
   • Extension of expiration dating supported by stability data.
   • Minor changes to the manufacturing process.

3. Minor Changes (Annual Report):
   These changes have minimal potential to impact the product’s quality, safety, or efficacy. They are reported in the Annual Report. Examples include:

   • Changes to container labels (not affecting safety information).
   • Editorial changes in the prescribing information.
   • Minor equipment changes that do not impact product quality.

Regulatory Pathways:

1. Prior Approval Supplement (PAS):
   For major changes, the applicant submits a supplement to the FDA for review and approval before making the change.

2. Changes Being Effected in 30 Days (CBE-30):
   For certain moderate changes, the applicant notifies the FDA at least 30 days before implementing the change. If the FDA does not raise objections within 30 days, the change may be implemented.

3. Changes Being Effected (CBE-0):
   For other moderate changes, the change can be implemented immediately upon FDA notification.

4. Annual Report (AR):
   Minor changes are included in the Annual Report submitted to the FDA.

Key Regulatory Guidelines and References:

1. FDA Guidance for Industry – Changes to an Approved NDA or ANDA (April 2004).
2. 21 CFR Part 314.70 (for NDAs and ANDAs).
3. FDA Guidance for Industry – Changes to an Approved Application for Biological Products (July 1997) (for BLAs).
4. ICH Q12 – Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management (for managing post-approval changes globally).

Practical Considerations:

• Risk Assessment: The applicant must conduct a risk assessment to determine the appropriate category for the change.
• Documentation: Adequate data and documentation must be submitted to support the change.
• FDA Timelines: Review times vary depending on the category of the change (e.g., PAS may take months, while AR is submitted yearly).
• Communication with FDA: It is often beneficial to discuss complex changes with the FDA in advance via a Pre-Supplemental Meeting.

For more details drop us an email at info@pharmregneoteric.com